Bioneer Corporation (064550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioneer Corporation (064550) has a cash flow conversion efficiency ratio of 0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩860.54 Million ≈ $583.18K USD) by net assets (₩229.21 Billion ≈ $155.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioneer Corporation - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Bioneer Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Bioneer Corporation carry for a breakdown of total debt and financial obligations.
Bioneer Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioneer Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hirequest Inc
NASDAQ:HQI
|
0.015x |
|
Bank Windu Kentjana Int
JK:MCOR
|
0.014x |
|
ALM Equity AB Pfd.
ST:ALM-PREF
|
-0.015x |
|
Mahamaya Steel Industries Limited
NSE:MAHASTEEL
|
-0.024x |
|
Daewon Pharm
KO:003220
|
-0.065x |
|
Ensari Deri Gida Sanayi ve Ticaret AS
IS:ENSRI
|
0.094x |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
-0.145x |
|
Kangda International Environmental Company Limited
STU:27K
|
0.001x |
Annual Cash Flow Conversion Efficiency for Bioneer Corporation (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bioneer Corporation from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 064550 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩226.89 Billion ≈ $153.76 Million |
₩-13.48 Billion ≈ $-9.13 Million |
-0.059x | -437.31% |
| 2023-12-31 | ₩234.88 Billion ≈ $159.17 Million |
₩4.14 Billion ≈ $2.80 Million |
0.018x | -52.80% |
| 2022-12-31 | ₩236.00 Billion ≈ $159.94 Million |
₩8.81 Billion ≈ $5.97 Million |
0.037x | -85.75% |
| 2021-12-31 | ₩203.05 Billion ≈ $137.60 Million |
₩53.17 Billion ≈ $36.04 Million |
0.262x | -60.16% |
| 2020-12-31 | ₩145.61 Billion ≈ $98.68 Million |
₩95.71 Billion ≈ $64.86 Million |
0.657x | +459.95% |
| 2019-12-31 | ₩30.61 Billion ≈ $20.74 Million |
₩-5.59 Billion ≈ $-3.79 Million |
-0.183x | +12.25% |
| 2018-12-31 | ₩38.99 Billion ≈ $26.42 Million |
₩-8.11 Billion ≈ $-5.50 Million |
-0.208x | -44.77% |
| 2017-12-31 | ₩27.15 Billion ≈ $18.40 Million |
₩-3.90 Billion ≈ $-2.64 Million |
-0.144x | +8.26% |
| 2016-12-31 | ₩26.11 Billion ≈ $17.70 Million |
₩-4.09 Billion ≈ $-2.77 Million |
-0.157x | -1427.23% |
| 2015-12-31 | ₩34.53 Billion ≈ $23.40 Million |
₩407.68 Million ≈ $276.28K |
0.012x | +108.26% |
| 2014-12-31 | ₩30.20 Billion ≈ $20.47 Million |
₩-4.31 Billion ≈ $-2.92 Million |
-0.143x | -- |
About Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more